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Available online 11 October 2016Symptoms of early hepatocellular carcinoma (HCC) often go unnoticed, so more than half of patients with
primary HCC are diagnosed after their disease has already reached an intermediate or advanced stage, or after
portal hypertension has appeared. While hepatic resection is widely recognized as a ﬁrst-line therapy to treat
very early or early HCC, its use in treating intermediate or advanced HCC or HCC involving portal hypertension
remains controversial. Here we review PubMed-indexed literature covering the use of hepatic resection for
such patients. The available evidence strongly suggests that, as a result of improvements in surgical techniques
and perioperative care, hepatic resection can beneﬁt many patients with intermediate or advanced HCC or
with HCC associated with portal hypertension.
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Prevalence of hepatocellular carcinoma (HCC) is increasing in some
countries [1]. Although past decades have seen great progress inral Science Foundation of China
(No. 16PJD004) and State Key
-016).
rgery Hospital, Second Military
angtian6666@hotmail.com
. This is an open access article underdiagnosis of HCC, treatment options remain limited, particularly for
those whose disease is diagnosed in intermediate or advanced stages.
For example, ofﬁcial guidelines [2–5] recommend the oral multikinase
inhibitor sorafenib for patients with advanced HCC and Child-Pugh A
liver function for whom locoregional therapy is unsuitable. However,
sorafenib prolongs median overall survival (OS) by only 2–3 months
and is associated with higher rates of adverse events and higher cost
than the best supportive care [6–7]. The more aggressive approach of
hepatic resection is a safe and effective option for many patients with
intermediate, advanced or complicated HCC, and indeed many liver
care centers,make use of this treatment [8–12]. This reﬂects remarkable
advances in radiological technology [13–14], surgical techniques, and
perioperative care. However, some liver care centers and ofﬁcialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients [15–29].
Hepatic resection is a well-established, popular curative treatment
for patients with good liver function and HCC satisfying the Milan
criteria, which involves up to 3 lesions b3 cm or a single lesion b5 cm
and no extrahepatic manifestations or vascular invasion [30]. The
5-year OS of such patients exceeds 50% after hepatic resection
[31–33]. Unfortunately, since the symptoms of early HCC often go
unnoticed, more than half of patients with primary HCC are diagnosed
after their disease has already reached an intermediate or advanced
stage [34–35]. Most of these patients have developed multinodular
tumors or macrovascular invasion; in addition, a substantial proportion
has portal hypertension because HCC often co-occurs with liver
cirrhosis. Based on Western ofﬁcial guidelines, none of these patients
should be offered hepatic resection as ﬁrst-line therapy. Instead, they
should be offered largely palliative treatments, such as sorafenib or
radioembolization [2–3].
Substantial evidence exists that a substantial number of such
patients can, in fact, beneﬁt fromhepatic resection, as reﬂected in expert
consensus statements [36–37] and ofﬁcial guidelines from Asian liver
health organizations [4–5]. However, this contrasts strongly with the
ofﬁcial guidelines from the US3 and Europe [2], particularly the author-
itative Barcelona Clinic Liver Cancer (BCLC) staging and treatment
system [38]. In this review, we examine the evidence for the safety
and efﬁcacy of hepatic resection for patients with large multinodular
HCC or HCC involving macrovascular invasion or portal hypertension.
2. Staging systems
Several systems have been proposed for staging HCC, including
Cancer of the Liver Italian Program (CLIP) [39], French Score [40],
BCLC staging [38], Chinese University Prognostic Index [41], Japan
Integrated Staging (JIS) Score [42], Hong Kong Liver Cancer (HKLC)
system [43], Italian Liver Cancer (ITA.LI.CA) system [44], and the
Model to Estimate Survival for HCC patients (MESH score) [45]. Only
the BCLC [38] and HKLC [43] staging systems also recommend stage-
appropriate treatmentmodalities. Studies suggest that the BCLC system
can predict prognosis more accurately for Caucasian HCC patients than
Asian ones, while the converse is true of the HKLC staging system
[46–50]. However, even these widely used staging systems leave large
treatment gaps: indeed, many patients with HCC do not fall neatly
into their pre-speciﬁed treatment pathways [49], and even patients
within the same BCLC or HKLC stage can differ substantially. For exam-
ple, the BCLC classiﬁes intermediate HCC as disease involving 2–3 tu-
mors with a maximum diameter N3 cm or N3 tumors of any diameter
[51–54]. The present review focuses on the BCLC system, since it is the
only one endorsed by the European Association for the Study of the
Liver [2] and the American Association for the Study of Liver Disease [3].
3. Intermediate HCC
HCC involving 2–3 tumors with a maximum diameter N 3 cm or N3
tumors of any diameter is classiﬁed as intermediate disease [52–55].
Recommended treatments for such patients include transarterial
chemoembolization (TACE), radioembolization, or sorafenib, but not
hepatic resection. Although the initial version of the BCLC system
classiﬁed HCC involving a single large tumor (N5 cm) as intermediate
stage [38], and still guidelines are unclear and somehow contradictory
in this sense as recently pointed out [10,11], although recent reviews
written by BCLC proponents seems trying to recalibrate their position
stating that a single-HCC, regardless of tumor size, should be considered
as an early stage disease [52–55]. Anyhow for patients with single HCC,
hepatic resection is ﬁrst-line therapy.
This approach of stratifying patients by tumor size goes against a
substantial body of evidence from studies in Western and Asian
countries that hepatic resection can be safe and effective in patientswith single and multinodular HCC, regardless of tumor size, so long
as resection is feasible based on tumor location and preserved liver
function [10,56–89]. This highlights the need to expand ofﬁcial indica-
tions for hepatic resection [20–22].
Ofﬁcial guidelines also fail to reﬂect available evidence by continuing
to recommend TACE when its efﬁcacy is far from clear, particularly in
comparison with hepatic resection. Median OS for patients with inter-
mediate HCC following TACE is approximately 14 months [52–54]. In
contrast, a systematic review of 50 studies involving 14,808 patients
with large ormultinodular HCC foundmedianOS after hepatic resection
to be 81% at 1 year, 56% at 3 years, and 42% at 5 years [90]. The corre-
sponding OS for 4945 patients with multinodular HCC was 75%, 48%,
and 30%, while disease-free survival (DFS) was 60%, 32%, and 25% [91].
Largemeta-analyses have suggested that hepatic resection is associated
with better overall survival than TACE [92–93], and this was also
demonstrated in a parallel comparison in a randomized controlled
trial of 173 patients with multinodular HCC outside Milan criteria [94].
Substantial evidence, then, exists that hepatic resection is
associated with better survival than TACE or sorafenib, raising the
possibility that ofﬁcial guidelines are restricting many patients
with intermediate HCC to palliative therapy when they could beneﬁt
from more aggressive resection. It is true that some situations may
limit the safety or efﬁcacy of resection. For example, liver cirrhosis
may increase the risk of perioperative morbidity and mortality
[95]. In addition, resection may be less effective in patients with
larger or multiple tumors because of the possibility of vascular
invasion and organ metastasis [96]. Indeed, the size and number of
tumors are associated with OS and DFS [88]. Nevertheless, continu-
ous improvements in surgical technique and perioperative care
support expanding ofﬁcial indications of hepatic resection.
4. Advanced HCC
In China, nearly half of patients with primary HCC are diagnosed
in an advanced stage [35]. Most of these patients present with portal
vein tumor thrombus (PVTT). One study compared Chinese patients
with advanced HCC who received either initial hepatic resection
(n = 339) or TACE (n = 105) [97]. Most of those patients (83%)
had a tumor thrombus, 12% suffered preoperative tumor rupture,
14% had distant metastases, and 5% had lymph node invasion.
Patients receiving either treatment showed similar postoperative
morbidity as well as mortality at 30 and 90 days. However, patients
in the resection group showed signiﬁcantly longer median survival
than those in the TACE group (16.4 vs. 11.8 months, P = 0.012).
Other studies support these ﬁndings, even after using propensity
score matching to reduce potential confounding due to patient
differences at baseline [98–100].
Hepatic resectionmay be uniquely effective for patients who experi-
ence preoperative tumor rupture [101–103]. When a resectable tumor
ruptures, emergency or staged resection can save the patient's life. In
fact, hepatic resection is often the only option in the event of spontane-
ous tumor rupture. If a patient recovers hemostasis, staged resection
may lead to better long-term OS than emergency resection [101].
Further work is needed to improve resection techniques or explore
(neo)adjuvant therapies that can be administered in combination, in
order to improve the relatively low long-term OS of patients who
undergo resection following spontaneous tumor rupture. Certainly if
surgery remains a suitable treatment for these complicated patients it
is surprising not considering this treatment suitable for the advance
HCC once approached not in emergency.
Numerous studies, mostly from Asian countries, indicate that hepat-
ic resection can be safe and effective in patients with HCC involving
PVTT. For example, a large retrospective study from Japan compared
OS of 2093 HCC patients with PVTT who underwent hepatic resection
and 4381 patients who received other treatments [104]. Median OS
was signiﬁcantly longer in the resection group (2.87 yr) than in the
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survival beneﬁt of 1.77 years for hepatic resection. Notably, hepatic
resection showed no OS beneﬁt among patients in whom PVTT affected
the main trunk or contralateral branch (Vp3 or 4). A large multicentric
study recruiting patients from Asia and Western countries showed
long-term survival approaching 40% at 5 years when surgery was
offered to these patients [10]. Our systematic review of 24 studies in-
volving 4389 patients with HCC involving macrovascular invasion
showed that hepatic resection was associated with median OS
from 18% at 5 years to 50% at 1 year [90]. Conversely, median OS for
such patients once treatedwith sorafenib ranged from 6.5–10.7 months
[6–7] and from 5.4–10 months in presence of PVTT [105–106].
Radioembolization using yttrium-90 microspheres is associated with
median OS of 8.8–13.8 months in patients with HCC and PVTT
[105–106]. These median OS rates are not much higher than the
rates of 4.2–7.9 months associated to the best supportive care [6–7].
Therefore, the survival beneﬁt of sorafenib or radioembolization
therapy is not obvious, also considering that these treatments come
with risk of adverse events and high costs that can be prohibitive for
medical centers or patients.
These considerations argue for expanding ofﬁcial guidelines to
recognize hepatic resection as a therapeutic option for selected patients
with advanced HCC and preserved liver function. Surgeons should not
shy away from this option when it is feasible, though they should be
prepared for the fact that the procedure is technically demanding. On
the other hand, for patients whose PVTT has invaded the main trunk
or contralateral branch, then radioembolization and sorafenib, alone
or in combination, may be appropriate.
5. HCC involving portal hypertension
Portal hypertension may affect treatment outcomes of patients with
decompensated cirrhosis, in whom such hypertension manifests
as ascites and esophageal varices. Portal hypertension is typically
diagnosed indirectly from the presence of at least one of the following:
gastric and/or esophageal varices detectable by endoscopy and/or
computed tomography, splenomegaly with a platelet count below
100,000/mm3, or hypertensive gastropathy. These surrogate signs can
be inaccurate, since some patients diagnosed indirectly with portal hy-
pertension turn out not to meet the pressure cut-off of ≥10 mmHg
[107]. A promising non-invasive indirect marker of portal hypertension
may be liver stiffness estimated by transient elastography [108–110].
Ideally, the pressure gradient in the hepatic vein should be measured
directly before surgery in patients with clinically signiﬁcant portal
hypertension.
Ofﬁcial guidelines from the West [2–3], while not regarding portal
hypertension as an absolute contraindication of hepatic resection, do
not recommend resection as ﬁrst-line therapy. This is because resection
in the presence of portal hypertension is associated with higher mortal-
ity at 30 and 90 days and greater risk of postoperative decompensation,
as well as higher mortality at 3 and 5 years [111–119]. This reﬂects the
higher frequency of comorbidities and cirrhosis among HCC patients
with portal hypertension. Other evidence, much of it from these same
studies, suggests that at least for certain patients with portal hyperten-
sion, hepatic resection may be safe and effective. Propensity score
matching based on baseline characteristics showed similar mortality
at 30 and 90 days for patients with or without portal hypertension
[113,119]. In addition, short- and long-term OS as well as recurrence
rates were similar between patients with or without portal hyperten-
sion when only patients with early HCC or patients who underwent
minor hepatectomy were included in the analysis [119]. A systematic
review concluded that although median perioperative mortality was
6.7% among patients with portal hypertension, median OS/DFS was
82/70% at 1 year, 71/50% at 3 years, and 37/38% at 5 years [120].
On balance, then, the available evidence suggests that hepatic
resection can be appropriate for at least a subset of patients with HCCinvolving portal hypertension. To clarify the indications for this treat-
ment approach, it would be helpful to know how resection compares
with other treatments for patients with portal hypertension, such as ra-
diofrequency ablation, TACE, and liver transplantation. Fewstudies have
addressed this question. In a retrospective study of patients with very
early or early HCC (BCLC staging) and portal hypertension who
underwent resection (n = 81) or radiofrequency ablation (n = 40),
5-year OS for the two groups was similar, although resection was asso-
ciated with better 5-year DFS. Inverse probability weighting of the data
led to similar results [121]. In a large rretrospective study of patients
with portal hypertension who underwent resection (n = 173) or
TACE (n = 80), resection was associated with signiﬁcantly higher OS
at 1 year (76% vs. 73%), 3 years (38% vs. 17%), and 5 years (16% vs. 7%)
(P b 0.001) [88]. This evidence, while scant, supports the safety and
efﬁcacy of resection for selected patients with portal hypertension.
This small evidence base has yet to identify prognostic factors that
may predict post-resection outcomes for HCC patients with portal
hypertension. Such factors may help clinicians exclude certain patients
because of unacceptably high risk of perioperative death. Until more de-
tailed analyses can be performed, clinicians should screen candidates
for hepatic resection based on general health status, tumor size and
number, vascular invasion, extrahepatic metastasis, preserved liver
function, comorbidities, extent of hepatectomy, and residual hepatic
volume. In general, major hepatectomy is not recommended in patients
with cirrhosis. The relatively high 90-day mortality rate and complicat-
ed resection procedure in patients with portal hypertension mean that
clinicians should carefully consider which treatment approach is likely
to give the patient the best long-term OS.
6. Perspectives
Ofﬁcial guidelines have proven extremely useful for guiding re-
search and treatment of HCC. However, despite the sometimes substan-
tial evidence indicating the safety and efﬁcacy of hepatic resection for
patients with intermediate or advanced HCC or with HCC involving
portal hypertension, ofﬁcial guidelines of US and European associations
do not recommend it as a treatment option.
On the other hand, there is enough room of data to suggest nomo-
gram based criteria for addressing patients to surgery based on their
peculiar clinical proﬁle [122–123]. This suggests that expanding the
criteria for selecting patients for hepatic resection can increase access
to potentially greater clinical beneﬁts without signiﬁcantly increasing
in-hospital mortality or other adverse outcomes. The efﬁcacy of resec-
tion may, in many patients, be higher when combined with other treat-
ment modalities, which has only begun to be investigated [124–126].
7. Conclusions
Hepatic resection to treat HCC is associated with the best outcomes
when the patient has only one tumor and no macrovascular invasion
or portal hypertension. Various and worldwide spread reports suggest
that surgery could be a proper treatment also for many patients with
intermediate or advanced disease or with disease involving portal
hypertension, as long as preserved liver function is adequate. There is
now room, rather than debating whether or not surgery should have a
room for these patients, for focusing better on selection criteria to
further enhance the prognostic beneﬁts of resection.
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